PGDx elio tissue complete
Commercial- Indications
- Solid tumors
Company intelligence / Profile preview
GenoME Diagnostics
Belfast, Northern Ireland, United Kingdompersonalgenome.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
GenoME Diagnostics' lead product, OvaME, aims to enable earlier and more accurate diagnosis of ovarian cancer through a blood-based test. The company leverages a decade of research from Queen’s University Belfast and utilizes advanced biomarker discovery technologies. No clinical trial results have been published as of June 2025.
- Therapeutic areas
- OncologyOther
- Modalities
- Device (diagnostic test)Biomarker-based diagnosticsLiquid biopsy technology
- Industry
- Molecular Diagnostics
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on GenoME Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenoME Diagnostics.